Prospective data from the MGH National Pregnancy Registry for Psychiatric Medications identified 56 pregnancies with first‑trimester exposure to vortioxetine (Trintellix). Among the 56 evaluable outcomes, the investigators observed no major malformations. Data collection included maternal postpartum interviews, medical‑record review, and adjudication of malformations by a dysmorphologist who was blinded to medication exposure.
Vortioxetine is an antidepressant approved in the United States in 2013 for major depressive disorder in adults. Compared with older antidepressants—such as many selective serotonin reuptake inhibitors (SSRIs), venlafaxine, duloxetine, and bupropion—reproductive safety data for newer agents like vortioxetine have been relatively sparse. The limited number of reported pregnancy exposures to vortioxetine has constrained prior assessment of teratogenic risk.
The MGH National Pregnancy Registry for Psychiatric Medications is a prospective pharmacovigilance program that enrolls pregnant people with a history of psychiatric illness and follows them through the postpartum period. Enrollment and data collection occur before the pregnancy outcome is known, which reduces recall and reporting biases that affect retrospective case series or voluntary reports.
For the analysis described by Freeman and colleagues (Journal of Clinical Psychopharmacology), investigators identified women enrolled in the Registry who reported taking vortioxetine during the first trimester. Outcome ascertainment combined maternal postpartum interview and medical‑record review. A dysmorphologist, blinded to exposure status, adjudicated suspected major malformations to provide an independent assessment.
As reported in the source, outcome data for 56 women with first‑trimester vortioxetine exposure were evaluable as of March 26, 2026.
Among the 56 pregnancies with first‑trimester exposure to vortioxetine, investigators found zero cases of major malformations. The outcome assessment relied on prospective enrollment, interview, and medical records, with blinded adjudication by a dysmorphologist.
These prospective findings are reassuring in that they did not identify a signal to suggest vortioxetine is a major teratogen. However, the source emphasizes several important limitations:
The sample size is small. Observing no major malformations among 56 exposed pregnancies does not establish safety and cannot exclude a modest increase in risk or detect rare malformations.
There was no comparison group in this report; an appropriate reference population is necessary to estimate relative risk.
The analysis focused only on major structural malformations after first‑trimester exposure. It did not address other clinically relevant outcomes such as miscarriage, pregnancy complications, preterm birth, neonatal adaptation symptoms, or longer‑term neurodevelopmental outcomes.
Because of these limitations, larger numbers of exposed pregnancies and inclusion of comparison groups will be required to generate more precise risk estimates.
The Registry data add systematically collected evidence to the sparse literature on vortioxetine exposure in pregnancy, and the absence of observed major malformations in this cohort offers some reassurance. Nevertheless, the findings do not prove safety.
When initiating or continuing an antidepressant in people who are pregnant or planning pregnancy, clinicians should individualize decisions. Considerations include:
For patients already doing well on vortioxetine, the potential harms of switching—relapse or loss of therapeutic effect—should be weighed against uncertain reproductive risks.
The MGH National Pregnancy Registry for Antidepressants continues to enroll pregnant people age 45 and younger with a history of psychiatric illness. The registry accepts participants who did and did not take an antidepressant during pregnancy. Continued recruitment is necessary to obtain larger samples and more precise estimates of reproductive risks associated with vortioxetine and other newer antidepressants.
The source lists a contact number for the registry: 1‑866‑961‑2388, and refers to the Registry website for additional information on participation.
Freeman MP, Viguera AC, Manuelian AM, Grassi EJ, Murphy BB, Cohen LS. Pregnancy Outcomes After First‑Trimester Exposure to Vortioxetine: Prospective Outcomes From the MGH National Pregnancy Registry for Psychiatric Medications. Journal of Clinical Psychopharmacology. Published online June 29, 2026.
(Article authored for the MGH Center for Women’s Mental Health. Details in this summary are limited to the information reported in the original source.)